Cultural Heritage
Qizheng Tibetan Medicine Achieves Record-Breaking Performance in 2024; Consistent and Stable Dividends Highlight Strong Growth Momentum.
Release time:
2025-04-26 13:31
Qizheng Tibetan Medicine (002287) disclosed its annual report, revealing that the company achieved another record high in its 2024 operating performance, with both revenue and net profit excluding non-recurring items posting double-digit year-on-year growth. The company’s revenue reached RMB 2.338 billion, and its net profit attributable to shareholders of the listed company, excluding non-recurring gains and losses, amounted to RMB 426 million.
According to the financial report, in 2024, Qizheng Tibetan Medicine saw an increase in market coverage across multiple products, with sales growing year-on-year. Products such as Pain Relief Plaster, White Meridian Ointment, Ruyi Zhenbao Tablets, Ten-Flavor Gentian Flower, Six-Flavor Nengxiao Tablets, and Honghua Ruyi Pills all demonstrated strong growth momentum. The company’s comprehensive marketing efforts have yielded significant results, further enhancing its industry standing. It was listed on the “Top 100 Pharmaceutical Industry Comprehensive Competitiveness 2024” and the “Top 50 Traditional Chinese Medicine Industry Comprehensive Competitiveness 2024” by the China Pharmaceutical Association, with a brand value of 3.15 billion yuan.
In terms of profit distribution, Qizheng Tibetan Medicine places great importance on shareholder returns. The company plans to distribute a cash dividend of 3.8 yuan (including tax) for every 10 shares held by all shareholders based on its 2024 operating results.
It is worth noting that on December 30, 2024, in response to the spirit of relevant policies such as the "Several Opinions of the State Council on Strengthening Regulation, Preventing Risks, and Promoting High-Quality Development of the Capital Market" and the "Opinions (Trial) on Strengthening the Supervision of Listed Companies" issued by the China Securities Regulatory Commission, the company has introduced a special dividend proposal. This move aims to enhance investors’ sense of gain, boost their confidence in the company’s future development, and align with the company’s overall development strategy and actual operating conditions.
In January 2025, the company completed the distribution of special dividends for 2024, with a dividend amount of 117 million yuan. Combined with the anticipated cash dividend of 201 million yuan this time, the total projected cash dividend amounts to 318 million yuan. The total cash dividend represents 54.66% of the net profit attributable to shareholders of the listed company in 2024.
To date, Qizheng Tibetan Medicine has distributed cash dividends 16 times, with cumulative cash dividend payments totaling 2.694 billion yuan. Among these, the cumulative dividends (including share repurchases) over the past three years represent approximately 150% of the company’s average annual profit during that period, fully demonstrating the company’s solid financial position and its consistently stable dividend policy.
Feng Ping, Senior Vice President and Board Secretary of Qizheng Tibetan Medicine, stated: “Qizheng Tibetan Medicine has always adhered to a long-term value-oriented approach, committed to establishing a sustainable dividend mechanism, and deeply sharing the fruits of our business development with investors. We aim to provide investors with consistent and stable cash dividends, thereby genuinely enhancing their sense of value and bolstering their confidence in long-term investment.”
As a leading enterprise in the modernization of Tibetan medicine, Qizheng Tibetan Medicine has maintained steady and sustained growth in its performance over the years, actively fulfilling its social responsibilities and creating sustainable value for all stakeholders, including investors.
Reporting media: Panorama Network
Report link: https://www.p5w.net/roll/company/202504/t20250425_6354296.htm
Copyright Qizheng Tibetan Medicine Co., Ltd. All rights reserved. ICP Filing Number:
Internet drug information service qualification certificate number:（藏） Non-Commercial - 2018-0004 SEO